Surrozen, Inc. reported a net loss of $183.2 million for the fourth quarter of 2025, or $20.13 per share, and a full‑year loss of $242.0 million, or $32.37 per share. Total revenue for the year was $3.5 million, down from $10.7 million in 2024, while cash and cash equivalents rose to $89.2 million at year‑end, up from $81.3 million at the end of September 2025, reflecting proceeds from an at‑market sale program and warrant exercises.
The large GAAP loss is largely attributable to non‑cash financing charges. Surrozen incurred losses on the execution of its 2025 PIPE, changes in the fair value of tranche liability, and warrant‑related expenses, all of which are one‑time items that do not reflect ongoing operating performance. When these items are excluded, the company’s operating loss is substantially smaller, underscoring that the core business remains under development rather than in decline.
Revenue fell 67% year‑over‑year because the company did not receive the $5 million milestone payment it had earned in 2024 from its partnership with Boehringer Ingelheim. The absence of that payment, combined with the company’s focus on advancing its ophthalmology pipeline, explains the sharp drop in top‑line numbers. R&D expenses rose to $7.8 million in Q3 2025, a 50% increase from the prior year’s $5.2 million, reflecting intensified investment in its lead retinal candidates.
Surrozen’s management highlighted its strategic focus on ophthalmology. “2025 was a year of significant momentum as we progressed two lead product candidates in retinal vascular disease, advanced our platform for developing multifunctional biologic candidates that selectively activate Wnt signaling in combination with other key disease pathways and further strengthened our management team to drive our long‑term growth strategy,” said President and CEO Craig Parker. Parker added, “2026 is an exciting year for us as we expect to submit an IND application for SZN‑8141 in the second half of the year and continue our focus on developing therapeutics that address critical unmet needs in retinal diseases.” The company also received a $5 million milestone payment from Boehringer Ingelheim for its SZN‑413 partnership, further validating its Wnt platform.
Analysts reacted positively to the earnings release, citing the company’s improved liquidity, the progress of its ophthalmology pipeline, and the milestone payment from Boehringer Ingelheim as key drivers of optimism. The focus on a second‑tranche PIPE trigger tied to FDA clearance of SZN‑8141 signals confidence in the company’s ability to secure future funding once regulatory milestones are met.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.